Prelude Therapeutics signs Incyte option deal, to get $35 million cash and $25 million stock sale

Prelude Therapeutics Incorporated signed an exclusive option agreement with Incyte Corporation on November 3, 2025, covering its JAK2V617F JH2 inhibitor program. The company reported the agreement in a Form 8-K filed November 4, 2025, along with a separate share sale to Incyte and changes in management.

What Incyte gets and what Prelude keeps

Under the option, Incyte receives an exclusive right to acquire Prelude's entire interest in assets tied to the program, including the company's library of preclinical candidates. The program is aimed at patients with myeloproliferative neoplasms, or MPNs. Prelude will receive $60 million in capital: an initial $35 million in cash, plus a $25 million equity investment by Incyte. The company expects to keep advancing the program toward an IND-ready data package, the material needed to support an investigational new drug application.

Incyte may exercise the option from the effective date until the later of 30 days after Prelude delivers that package or 15 months after the effective date. The 15-month period extends while Prelude delivers the package, but the extension cannot exceed three months unless the parties agree. If Incyte exercises, it would pay $100 million under an asset purchase agreement attached to the option. Prelude would then be eligible for up to $775 million in additional clinical and regulatory milestones and single-digit royalties on global net sales, for total potential cash payments of up to $910 million. If Incyte does not exercise, the assets stay with Prelude.

The filing describes the program's next step as an IND-ready package, not clinical results, and it presents no trial data for the program.

The $25 million share purchase

On the same day, Prelude signed a securities purchase agreement under which Incyte agrees to buy 6,250,000 shares of Prelude's non-voting common stock at $4.00 a share, for $25 million. Incyte may convert those shares into voting common stock at any time, subject to a beneficial ownership limit in the company's charter. The purchase has not closed. Closing is expected within five business days after the closing conditions are met.

The shares are exempt from registration under Section 4(a)(2) of the Securities Act, based in part on Incyte's representation that it is an accredited investor buying for investment. Prelude agreed to file a Form S-3 resale registration within 60 days of Incyte's request, or no later than 30 days after closing. The company says it will use the initial option payment and the share proceeds to advance its pipeline, including the KAT6A and JAK2V617F programs, and for working capital. The 8-K names no placement agent, underwriter or financial adviser for either agreement.

Management changes and the SMARCA2 pause

Jane Huang, M.D., resigned as president and chief medical officer effective November 3, 2025. The 8-K says her resignation was not due to any disagreement with the company. Under a consulting agreement effective November 4, 2025, she will advise on clinical programs at $750 an hour until September 15, 2026, and her equity awards will keep vesting. Victor Sandor, M.D.C.M., a board member who chairs the Science and Technology Committee, will provide strategic and operational oversight of clinical development until the same date. The 8-K describes him as the former chief medical officer of Array Biopharma.

Prelude also said it will pause clinical development of its first-in-class SMARCA2 degrader program as part of a strategic portfolio shift. The filing gives no timetable for that pause and no data on the program.

The company and what the filings leave out

The annual report on Form 10-K, filed March 10, 2025, describes Prelude as a clinical-stage precision oncology company. It says the company was founded in 2016, has received FDA clearance for multiple investigational new drug applications, and has moved several programs into clinical trials. The report also describes a discovery collaboration with AbCellera Biologics on degraders used as antibody payloads, and lists kinase, targeted protein degrader and antibody drug conjugate programs.

The 8-K gives no cash balance and no net loss. Its forward-looking statements mention the company's cash runway, but the filing gives no figure for it. Against a $35 million payment and a $25 million share sale, the filing leaves the length of Prelude's funding unstated.

Report an error

Companies in this story

PRLDPrelude Therapeutics IncorporatedNASDAQ · United StatesOpen the starter desk